IQVIA Holdings Inc. $IQV Stock Holdings Decreased by Sendero Wealth Management LLC

Sendero Wealth Management LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,403 shares of the medical research company’s stock after selling 3,733 shares during the quarter. IQVIA accounts for about 1.2% of Sendero Wealth Management LLC’s holdings, making the stock its 12th largest position. Sendero Wealth Management LLC’s holdings in IQVIA were worth $10,685,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Alliancebernstein L.P. raised its stake in IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the period. Boston Partners acquired a new stake in shares of IQVIA in the third quarter worth $676,698,000. Artisan Partners Limited Partnership grew its holdings in shares of IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after buying an additional 161,085 shares in the last quarter. Invesco Ltd. grew its holdings in shares of IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after buying an additional 367,204 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in IQVIA by 12.3% during the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after buying an additional 253,759 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 2.1%

Shares of IQVIA stock opened at $169.05 on Friday. The firm has a market cap of $28.69 billion, a price-to-earnings ratio of 21.51, a P/E/G ratio of 1.60 and a beta of 1.39. The stock has a 50-day simple moving average of $188.18 and a 200-day simple moving average of $205.38. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. BMO Capital Markets set a $250.00 price objective on IQVIA in a research report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Truist Financial dropped their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, Mizuho set a $215.00 target price on shares of IQVIA in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Buy” and a consensus target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.